Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Haematol ; 75(4): 346-51, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16146542

RESUMO

OBJECTIVES: Accumulating evidence suggests that non-T, non-B cell CD4+CD56+ neoplasms with lymphoblastic morphology include clinically and immunophenotypically diverse entities. Although their cells of origin or classification are still controversial several entities clearly represent a distinct type of neoplasms that are clinically aggressive. METHODS: In this work we present the immunophenotypic and genotypic features of bone marrow (BM), peripheral blood (PB), lymph node and skin lymphocytes from a patient diagnosed as plasmacytoid dendritic cell leukemia involving the skin, BM, PB, lymph nodes, liver and spleen. For determination of immunophenotypic characteristics of malignant plasmacytoid dendritic cells 73 monoclonal antibodies detecting lineage markers, chemokine receptors, cytokine receptors, activation, and co-stimulatory molecules were used. RESULTS AND CONCLUSION: The malignant cells proved to express CD4+, CD56+ lineage negative leukemia phenotype characteristically positive for CD36, CD38, CD40, CD45, CD45RA, CD68, CD123, CD184, HLA-DR, BDCA2, and granzyme-B corresponding to the preplasmacytoid dendritic cell developmental stage. The presence of CD11a/CD18, CD84, CD91, CD95, alphavbeta5, CDw197, and the absence of CD52 and CD133 in this case can be regarded as additional features of malignant cells. Completing the immunophenotypes with multidrug resistance function can provide additional information for characterizing pDC leukemia.


Assuntos
Células Dendríticas/patologia , Leucemia/patologia , Plasmocitoma/patologia , Idoso , Células Sanguíneas/patologia , Antígenos CD4 , Antígeno CD56 , Linhagem da Célula , Citometria de Fluxo , Humanos , Imunofenotipagem , Linfonodos/patologia , Masculino , Pele/patologia
2.
Cancer Immunol Immunother ; 53(9): 835-9, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15052374

RESUMO

The aim of this study was to determine the complement functions, the serum levels of the complement components C3 and C4, and circulating immune complexes during autologous blood stem cell transplantation. Seventeen lymphoma patients receiving transplants between 1997 and 2001 were involved in this study. High-dose chemotherapy with or without total body irradiation was used for conditioning. The transplantation resulted in complete remission without complications in 14 patients. Early relapse developed in one case and two nonrelapsed patients suffered from serious toxic infection early posttransplant. Normal values of CH50, C3, C4, and immune complexes in sera of patients were detected on day -7, before the conditioning (day of transplantation was determined as day 0). After the conditioning, on day -2, the levels of the CH50, C3, and C4 decreased significantly ( p<0.05) in all patients compared with the starting values. The CH50, C3, and C4 levels exceeded the starting values in the noninfected patients from day +7. In two patients suffering from toxic infection, significantly elevated complement levels were documented early posttransplant. In the relapsed patient a significant decrease of the complement parameters was documented posttransplant accompanied by a significant elevation in the immune complex level. The results show alteration in the complement parameters during transplantation, but in the complication-free cases this remained within the normal ranges. However, an unusual elevation seemed to be the sign of infection, and the significant decrease seemed to indicate a relapse.


Assuntos
Complexo Antígeno-Anticorpo/metabolismo , Complemento C3/metabolismo , Complemento C4/metabolismo , Doença de Hodgkin/metabolismo , Linfoma não Hodgkin/metabolismo , Transplante de Células-Tronco , Adulto , Ensaio de Atividade Hemolítica de Complemento , Feminino , Doença de Hodgkin/imunologia , Doença de Hodgkin/terapia , Humanos , Linfoma não Hodgkin/imunologia , Linfoma não Hodgkin/terapia , Masculino , Pessoa de Meia-Idade , Condicionamento Pré-Transplante , Transplante Autólogo , Irradiação Corporal Total
3.
Rheumatol Int ; 24(6): 359-61, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14986060

RESUMO

The authors report a rare case of a female patient diagnosed with mixed connective tissue disease (MCTD). After a few years in remission, the patient acquired herpes zoster infection followed by a disease flare. Disease activity was accompanied by the development of meningitis. To determine whether the meningitis was caused by the previous herpes virus infection or was aseptic meningitis associated with the activity of MCTD raised important differential diagnostic issues. Repeated laboratory assessments of the patient's sera and cerebrospinal fluid revealed leukocytopenia, high anti-U1 ribonucleoprotein autoantibody level, increased immune complex, and decreased complement concentrations. The administration of corticosteroids resulted in rapid improvements in clinical symptoms and laboratory indicators.


Assuntos
Herpes Zoster/diagnóstico , Meningite Asséptica/diagnóstico , Doença Mista do Tecido Conjuntivo/diagnóstico , Corticosteroides/uso terapêutico , Adulto , Feminino , Seguimentos , Herpes Zoster/tratamento farmacológico , Herpes Zoster/epidemiologia , Humanos , Meningite Asséptica/complicações , Meningite Asséptica/tratamento farmacológico , Doença Mista do Tecido Conjuntivo/complicações , Doença Mista do Tecido Conjuntivo/tratamento farmacológico , Medição de Risco , Índice de Gravidade de Doença , Resultado do Tratamento
4.
Pathol Oncol Res ; 9(2): 131-3, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12858220

RESUMO

Relapse is the main cause of treatment failure following hematopoietic stem cell transplantation for blastic phase chronic myeloid leukemia. Treatment options including donor lymphocyte infusion, second transplantation, interferon- and re-induction chemotherapy are often unsuccessful. We report a patient with blastic phase chronic myeloid leukemia relapsing after allogeneic stem cell transplantation. The post-transplant leukemia was characterized with B-lymphoid markers and multiple genetic abnormalities including double Ph-chromosomes. The disease was treated with three courses of salvage chemotherapy combined with donor lymphocyte infusion and bcr-abl tyrosine kinase inhibitor. The leukemia proved to be non-responsive both to immune therapy and STI 571. The presented case demonstrates the need for combination approaches in post-transplant relapsed leukemia and discusses the possible contributing mechanisms of STI-571 resistance.


Assuntos
Crise Blástica/terapia , Transplante de Medula Óssea , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Transfusão de Leucócitos , Piperazinas/uso terapêutico , Pirimidinas/uso terapêutico , Antineoplásicos/uso terapêutico , Linfócitos B/patologia , Benzamidas , Resistencia a Medicamentos Antineoplásicos , Inibidores Enzimáticos/uso terapêutico , Proteínas de Fusão bcr-abl/antagonistas & inibidores , Humanos , Mesilato de Imatinib , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Recidiva Local de Neoplasia/terapia , Proteínas Tirosina Quinases/antagonistas & inibidores , Indução de Remissão , Terapia de Salvação , Doadores de Tecidos , Transplante Homólogo , Resultado do Tratamento
5.
Acta Microbiol Immunol Hung ; 50(1): 55-65, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12793201

RESUMO

Reaction patterns of the 7th Human Leukocyte Differentiation Antigen Workshop blind panel adhesion molecules were studied on CD3/CD4, CD3/CD8, CD3/TCR gamma delta double positive T cells from peripheral blood of patients with chronic graft versus host disease (n = 8) and healthy controls (n = 4). Reactivity of 14 adhesion antibodies was tested by three-colour immunophenotyping. The mean proportion of CD3+ T cells (69 +/- 19%). CD3/CD8++ (31 +/- 13%) and CD3/TCR gamma delta++ (4 +/- 2%) T sub-populations of patients were comparable with the healthy controls. However, the mean percentage of CD3/CD4++ T cell subset in patients (14 +/- 12%) proved to be significantly decreased in comparison with the normal control value (34 +/- 16%) presumably due to secondary immunodeficiency. The workshop antibodies proved to be reactive with three T cell subsets expressing the examined antigens. Based on the results of the adhesion molecule workshop new CD categories have been introduced: CD156b as a transmembrane protein, CD167a as an epithelial tyrosin kinase receptor, CD168 as a receptor for hyaluronan mediated motility (RHAMM) and CD171 as a co-stimulatory adhesion molecule. There were significant differences in the expression of the CD167a and CD156b antigens on the CD3/CD4++ subset between the samples of patients compared with the controls characterizing the CD4+ T lymphocyte subpopulation in chronic graft versus host disease.


Assuntos
Antígenos CD/metabolismo , Doença Enxerto-Hospedeiro/imunologia , Proteínas de Membrana , Receptores de Antígenos de Linfócitos T gama-delta/metabolismo , Subpopulações de Linfócitos T/imunologia , Proteínas ADAM , Adulto , Complexo CD3/metabolismo , Antígenos CD4/metabolismo , Antígenos CD8/metabolismo , Doença Crônica , Proteínas da Matriz Extracelular/metabolismo , Feminino , Transplante de Células-Tronco Hematopoéticas , Humanos , Receptores de Hialuronatos/metabolismo , Imunofenotipagem , Masculino , Metaloendopeptidases/metabolismo , Pessoa de Meia-Idade , Subpopulações de Linfócitos T/metabolismo , Transplante Homólogo
6.
Cytokine ; 18(6): 340-3, 2002 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-12160523

RESUMO

We have investigated the influence of apo(a) genetics on the relationship between interleukin (IL)-6, and lipoprotein (a) [Lp(a)] levels in 154 patients with monoclonal gammopathy and 189 healthy subjects. No significant differences in Lp(a) levels and distribution of subjects with different sizes of apo(a) isoforms were found between patients and healthy controls. Relationship between IL-6 and Lp(a) levels was strongly dependent on the size of apo(a) isoforms. In patients with high-size apo(a) isoforms Lp(a) levels positively correlated (r=0.475, P=0.0007) to IL-6 concentrations, whereas no correlation was found in patients with low apo(a) isoforms. Our present finding may provide a plausible explanation for the contradictory findings about the acute phase protein nature of Lp(a).


Assuntos
Apolipoproteínas A/biossíntese , Apolipoproteínas A/química , Interleucina-6/biossíntese , Lipoproteína(a)/biossíntese , Paraproteinemias/metabolismo , Adulto , Idoso , Estudos de Casos e Controles , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/metabolismo , Polimorfismo Genético , Isoformas de Proteínas , Macroglobulinemia de Waldenstrom/metabolismo
7.
Haematologia (Budap) ; 32(4): 519-27, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12803128

RESUMO

An unusual case of hepatosplenic gamma delta T-cell lymphoma with leukemic phase in a 39-year-old woman is reported. At the first presentation she had splenomegaly and pancytopenia diagnosed as hypersplenia treated by splenectomy. Subsequently, she developed hepatomegaly and progressive neoplastic lymphocytosis. The bone marrow showed a sinusoidal infiltrate of medium-sized cells. Flowcytometric analysis of peripheral blood mononuclear cells demonstrated expression of CD3, CD7, CD16, CD56 antigens and T-cell receptor gamma delta. A monoclonal TCR gamma- and beta-chain gene rearrangement were detected by polymerase chain reaction. The patient was treated by traditional chemotherapy and alpha-interferon, unsuccessfully. Therefore, 2-chlorodeoxyadenosine was introduced resulting in a complete remission for 6 months. The reported case demonstrates the usefulness of 2-chlorodeoxyadenosine in treatment of hepatosplenic gamma delta T-cell lymphoma.


Assuntos
Antineoplásicos/uso terapêutico , Cladribina/uso terapêutico , Linfoma de Células T/tratamento farmacológico , Linfoma de Células T/imunologia , Receptores de Antígenos de Linfócitos T gama-delta/metabolismo , Adulto , Feminino , Hepatomegalia/tratamento farmacológico , Humanos , Linfoma de Células T/patologia , Recidiva , Indução de Remissão , Esplenomegalia/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...